Clinical trials: Acute Myeloid Leucemia
Acute Myeloid Leukemia
This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments, and to Identify and Functionally Validate, at the Single-cell Level, Biomarkers That Can Predict Response to Venetoclax.
The current classification of acute myeloid leukemias (AML) includes more than 20 different diseases, grouped based on their distinctive genomic characteristics, which reflect substantial heterogeneity.
- Trial name
- AMANITA (NCT07874100)
- Testing
- Bulk genotyping of AML samples at diagnosis and relapse, scRNA analysis at diagnosis, scRNAseq and genotyping analysis at day 28 after therapy, spatial transcriptomic analysis at day 0 and 28
- Where
- Italy
- Volunteers
- 420 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Acute Myeloid Leucemia
Single Cell Acute Leukemia Analysis
Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular.
- Trial name
- SCALA (NCT06906978)
- Testing
- blood sampling
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Acute Myeloid Leucemia, High-risk Myelodysplastic Syndrome (MDS)
Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital
The aim of the LANA bio-collection is to collect samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) or or high-risk myelodysplastic syndrome (MDS) to facilitate access to the leukemic or…
- Conditions
- Acute Myeloid Leucemia, High-risk Myelodysplastic Syndrome (MDS), Acute Lymphoid Leukemia
- Trial name
- LANA (NCT06681363)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Nantes University Hospital
Acute Myeloid Leucemia
F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)
PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution.
- Trial name
- AML F18-FLT (NCT01592266)
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization
AML (Acute Myelogenous Leukemia
Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations
Acute Myeloid Leukemia requires intensive chemotherapy treatment, usually followed by an allogeneic bone marrow transplant to reduce the risk of relapse.
- Trial name
- NCT07254611
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Venentoclax, Myeloid Malignancies
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) serves as a curative treatment modality for the vast majority of patients with hematological malignancies.
- Conditions
- Venentoclax, Myeloid Malignancies, Conditioning, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Trial name
- NCT07396480
- Testing
- Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan
- Where
- 18 sites in China
- Volunteers
- 186 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Acute Myeloid Leukemia, Minimal Residual Disease
Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
Study purpose is to assess the prognostic role of Minimal Residual Disease (defined as medullary expression of WT1 gene), performed at Baseline and during treatment according to clinical practice.
- Conditions
- Acute Myeloid Leukemia, Minimal Residual Disease, Wilms Tumor
- Trial name
- LAM-MMR (NCT02714790)
- Volunteers
- 281 people
- Sponsor
- A.O.U. Città della Salute e della Scienza